The company recently raised an additional $6.5 million to supplement the initial $11.6 million, which was announced in July 2014. HealthQuest Capital led the extension.
The funds will be used to support the company’s commercialization and marketing of its diagnostic arthroscopy product, Mi-eye.
More articles on devices:
27 spine devices receive FDA 510(k) clearance in January
MiMedx withdraws complaint against Organogenesis
NuVasive COO sells 15k shares — 5 things to know
